CervoMed (CRVO) director Frank Zavrl receives grant of 8,150 stock options

Rhea-AI Filing Summary

CervoMed Inc. director Frank Zavrl received a grant of stock options as part of his non-employee director compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock at an exercise price of $2.91 per share under the 2025 Equity Incentive Plan. These options vest monthly in substantially equal 1/12th increments over one year beginning June 30, 2026, contingent on his continued board service. Following this grant, Zavrl holds 8,150 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ZAVRL FRANK

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 8,150 options Exercise price: $2.91 per share Underlying shares: 8,150 shares +3 more

6 metrics

Stock options granted 8,150 options Grant to director Frank Zavrl on June 8, 2026

Exercise price $2.91 per share Strike price for 8,150 stock options

Underlying shares 8,150 shares Common stock covered by the option award

Post-grant option holdings 8,150 options Total stock options held following this grant

Option expiration June 8, 2036 Expiration date of granted stock options

Vesting period 1 year monthly Vests in 1/12th increments starting June 30, 2026

Key Terms

Stock Option (Right to Buy), 2025 Equity Incentive Plan, non-employee director compensation policy, vest on a monthly basis, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2025 Equity Incentive Plan financial

"granted an option ... under the Issuer's 2025 Equity Incentive Plan"

non-employee director compensation policy financial

"in accordance with the terms of the Issuer's non-employee director compensation policy"

vest on a monthly basis financial

"shares of common stock underlying the award will vest on a monthly basis"

continued service financial

"subject to the Reporting Person's continued service through the applicable vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZAVRL FRANK

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.91	06/08/2026		A		8,150		(1)	06/08/2036	Common Stock	8,150	$0	8,150	D

Explanation of Responses:

1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CervoMed (CRVO) director Frank Zavrl report?

Frank Zavrl reported receiving a grant of stock options to buy 8,150 CervoMed common shares. The award is part of the non-employee director compensation program and is structured as options rather than an immediate share purchase.

How many CervoMed (CRVO) shares are covered by Frank Zavrl’s new stock options?

The new stock option grant covers 8,150 shares of CervoMed common stock. Each option allows purchase at a fixed exercise price, giving Zavrl potential future equity exposure if he chooses to exercise the options.

What is the exercise price of Frank Zavrl’s CervoMed (CRVO) stock options?

The options have an exercise price of $2.91 per share. This means Zavrl can, once vested, buy CervoMed common shares at $2.91 regardless of the market price at the time of exercise, subject to the plan’s terms.

When do Frank Zavrl’s CervoMed (CRVO) stock options vest?

The options vest monthly over one year, in substantially equal 1/12th increments on the last day of each month starting June 30, 2026. Vesting is conditioned on Zavrl’s continued service on CervoMed’s board through each vesting date.

Under which plan were Frank Zavrl’s CervoMed (CRVO) options granted?

The options were granted under CervoMed’s 2025 Equity Incentive Plan. The award follows the company’s non-employee director compensation policy, providing equity-based incentives to outside directors instead of solely cash compensation.

How many CervoMed (CRVO) stock options does Frank Zavrl hold after this grant?

After this transaction, Zavrl holds 8,150 stock options directly according to the filing. This reflects the full size of the reported grant and represents his recorded derivative position in this specific Form 4.